Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | LYPLA1 | O75608 | 2/20 | 0.33 |
| ▸ | LYPLA2 | O95372 | 2/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.33 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.32 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | PTGFR | P43088 | 1/20 | 0.31 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10084617 | 1.00 | ALOX5 (0.44) | ALOX5DNM1LMNALYPLA1LYPLA2 | |
| SCHEMBL23282462 | 1.00 | ALOX5 (0.44) | ALOX5DNM1LMNALYPLA1LYPLA2 | |
| SCHEMBL23437455 | 1.00 | ALOX5 (0.44) | ALOX5DNM1LMNALYPLA1LYPLA2 | |
| SCHEMBL23923252 | 0.93 | ALOX5 (0.39) | ALOX5DNM1LMNA | |
| SCHEMBL15155771 | 0.88 | ALOX5 (0.62) | ALOX5ALDH1A1TBXA2RPTGFRPTGER2 | |
| SCHEMBL15155996 | 0.88 | ALOX5 (0.62) | ALOX5ALDH1A1TBXA2RPTGFRPTGER2 | |
| SCHEMBL15156129 | 0.88 | ALOX5 (0.62) | ALOX5ALDH1A1TBXA2RPTGFRPTGER2 | |
| SCHEMBL15155744 | 0.88 | ALOX5 (0.62) | ALOX5ALDH1A1TBXA2RPTGFRPTGER2 | |
| SCHEMBL31700901 | 0.88 | ALOX5 (0.53) | ALOX5DNM1LMNAALDH1A1SPHK2 | |
| SCHEMBL23390582 | 0.86 | ALOX5 (0.39) | ALOX5DNM1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 686 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240123047-A1 | LIPID NANOPARTICLE ADJUVANT COMPOSITION FOR PNEUMOCOCCAL CONJUGATE VACCINES | MERCK SHARP & DOHME LLC (US) | 2024-04-18 | — | — | US | claimed |
| US-11566051-B2 | Stabilized RSV F proteins and uses thereof | MERCK SHARP & DOHME LLC (US) | 2023-01-31 | — | — | US | claimed |
| EP-3939604-A2 | INFLUENZA HEMAGGLUTININ PROTEIN VACCINES | Merck Sharp & Dohme Corp. (US) | 2022-01-19 | — | — | EP | claimed |
| US-20210300971-A1 | STABILIZED RSV F PROTEINS AND USES THEREOF | MERCK SHARP & DOHME LLC | 2021-09-30 | — | — | US | claimed |
| CN-111655715-A | Stabilized RSV F proteins and uses thereof | 默沙东公司 | 2020-09-11 | — | — | CN | claimed |
| US-10576155-B2 | Low molecular weight cationic lipids for oligonucleotide delivery | SIRNA THEREAPEUTICS, INC. (US) | 2020-03-03 | — | — | US | claimed |
| EP-3556353-A2 | LIPID NANOPARTICLE VACCINE ADJUVANTS AND ANTIGEN DELIVERY SYSTEMS | MERCK SHARP & DOHME CORP. (US) | 2019-10-23 | — | — | EP | claimed |
| US-20190167811-A1 | LIPID COMPOSITIONS AND THEIR USES FOR INTRATUMORAL POLYNUCLEOTIDE DELIVERY | MODERNATX, INC. | 2019-06-06 | — | — | US | claimed |
| US-20180311176-A1 | NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES | TRANSLATE BIO MA, INC. (US) | 2018-11-01 | — | — | US | claimed |
| EP-3368089-A1 | NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES | TRANSLATE BIO MA, INC. (US) | 2018-09-05 | — | — | EP | claimed |
| US-20180000939-A1 | NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | SIRNA THERAPEUTICS, INC. (US) | 2018-01-04 | — | — | US | claimed |
| WO-2017192470-A1 | COMBINATION THERAPY OF ANTI-IL-10 ANTIBODY AND COMPOSITIONS COMPRISING LIPID NANOPARTICLES AND TLR9 AGONIST CPG OLIGONUCLEOTIDES | MERCK SHARP & DOHME CORP. (US) | 2017-11-09 | — | — | WO | claimed |
| WO-2017075038-A1 | NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES | RANA THERAPEUTICS, INC. (US) | 2017-05-04 | — | — | WO | claimed |
| US-20160361411-A1 | LIPID NANOPARTICLE VACCINE ADJUVANTS AND ANTIGEN DELIVERY SYSTEMS | MERCK SHARP & DOHME CORP (US) | 2016-12-15 | — | — | US | claimed |
| EP-2618847-A2 | NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | Merck Sharp & Dohme Corp. (US) | 2013-07-31 | — | — | EP | claimed |
| US-20130178541-A1 | NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | BANK OF AMERICA, N.A. | 2013-07-11 | — | — | US | claimed |
| WO-2012040184-A2 | NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | MERCK SHARP & DOHME CORP. (US) | 2012-03-29 | — | — | WO | claimed |
| US-12629412-B2 | Betacoronavirus mRNA vaccines | MODERNATX, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20130156849-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | modeRNA Therapeutics (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2012040184-A2 | NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | MERCK SHARP & DOHME CORP. (US) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180311176-A1 | NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES | DIS3, SYNCRIP, EXOSC5 | ALOX5 4111/4885DNM1 1458/4885LMNA 291/4885 |
| US-12629412-B2 | Betacoronavirus mRNA vaccines | RNMT, RNGTT, METTL16 | ALOX5 2873/4885DNM1 2514/4885LMNA 616/4885 |
| US-20180000939-A1 | NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | LDLR, APOB, CETP | ALOX5 1273/4885DNM1 624/4885LMNA 1763/4885 |
| US-10576155-B2 | Low molecular weight cationic lipids for oligonucleotide delivery | LDLR, APOB, CETP | ALOX5 1243/4885DNM1 486/4885LMNA 1800/4885 |
| US-20130156849-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | NSUN2, RNMT, NSUN3 | ALOX5 4052/4885DNM1 1918/4885LMNA 122/4885 |
| US-20160361411-A1 | LIPID NANOPARTICLE VACCINE ADJUVANTS AND ANTIGEN DELIVERY SYSTEMS | TLR3, TLR5, TLR1 | ALOX5 167/4885DNM1 3095/4885LMNA 1798/4885 |
| US-20190167811-A1 | LIPID COMPOSITIONS AND THEIR USES FOR INTRATUMORAL POLYNUCLEOTIDE DELIVERY | RNMT, PHOSPHO1, POLM | ALOX5 1911/4885DNM1 1045/4885LMNA 2115/4885 |
| US-20240123047-A1 | LIPID NANOPARTICLE ADJUVANT COMPOSITION FOR PNEUMOCOCCAL CONJUGATE VACCINES | PLTP, NAPEPLD, PHOSPHO1 | ALOX5 65/4885DNM1 2136/4885LMNA 1355/4885 |
| US-20130178541-A1 | NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | LDLR, LIPC, CETP | ALOX5 859/4885DNM1 627/4885LMNA 870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.